$SAVA
CASSAVA SCIENCES INC

2020 Q4 Form 10-Q Financial Statement

#000106953020000066 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.110M $1.040M $830.0K
YoY Change 32.14% 25.3% -2.35%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $2.620M $1.437M $779.0K
YoY Change 65.82% 84.47% -39.33%
Operating Profit -$1.437M -$779.0K
YoY Change 84.47% -39.33%
Interest Expense $10.00K $10.00K $80.00K
YoY Change -83.33% -87.5% 300.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.620M -$1.430M -$700.0K
YoY Change 72.37% 104.29% -44.88%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.620M -$1.430M -$697.0K
YoY Change 72.37% 105.16% -44.99%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$86.78K -$57.27K -$40.79K
COMMON SHARES
Basic Shares Outstanding 25.58M 24.92M 17.22M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $93.50M $24.10M $17.80M
YoY Change 304.76% 35.39% -12.75%
Cash & Equivalents $93.51M $24.07M $17.80M
Short-Term Investments
Other Short-Term Assets $488.0K $997.0K $385.0K
YoY Change 82.09% 158.96% 39.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $93.99M $25.07M $18.19M
YoY Change 302.56% 37.84% -12.22%
LONG-TERM ASSETS
Property, Plant & Equipment $11.00K $12.00K $61.00K
YoY Change -76.6% -80.33% -41.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K
YoY Change 0.0%
Total Long-Term Assets $306.0K $328.0K $186.0K
YoY Change 123.36% 76.34% 60.34%
TOTAL ASSETS
Total Short-Term Assets $93.99M $25.07M $18.19M
Total Long-Term Assets $306.0K $328.0K $186.0K
Total Assets $94.30M $25.40M $18.38M
YoY Change 301.52% 38.23% -11.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $911.0K $465.0K $340.0K
YoY Change 101.1% 36.76% -38.07%
Accrued Expenses $719.0K $558.0K $415.0K
YoY Change -7.46% 34.46% 38.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.865M $1.168M $907.0K
YoY Change 34.46% 28.78% 5.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $0.00
YoY Change
Total Long-Term Liabilities $0.00 $300.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.865M $1.168M $907.0K
Total Long-Term Liabilities $0.00 $300.0K $0.00
Total Liabilities $2.100M $1.426M $930.0K
YoY Change 51.41% 53.33% 7.89%
SHAREHOLDERS EQUITY
Retained Earnings -$174.9M -$172.3M -$167.1M
YoY Change 3.76% 3.13% 2.32%
Common Stock $35.00K $26.00K $17.00K
YoY Change 59.09% 52.94% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $92.20M $23.97M $17.45M
YoY Change
Total Liabilities & Shareholders Equity $94.30M $25.40M $18.38M
YoY Change 301.52% 38.23% -11.81%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$2.620M -$1.430M -$697.0K
YoY Change 72.37% 105.16% -44.99%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$1.200M -$2.200M -$700.0K
YoY Change 100.0% 214.29% -50.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.60M 1.000M 0.000
YoY Change 1096.61% -100.0%
NET CHANGE
Cash From Operating Activities -1.200M -2.200M -700.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 70.60M 1.000M 0.000
Net Change In Cash 69.40M -1.200M -700.0K
YoY Change 1209.43% 71.43% -106.42%
FREE CASH FLOW
Cash From Operating Activities -$1.200M -$2.200M -$700.0K
Capital Expenditures $0.00
Free Cash Flow -$700.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei City Area Code
CityAreaCode
512
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Type
DocumentType
10-Q
dei Entity Address Address Line1
EntityAddressAddressLine1
7801 N. Capital of Texas Highway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78731
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Central Index Key
EntityCentralIndexKey
0001069530
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25578673
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity File Number
EntityFileNumber
000-29959
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
CASSAVA SCIENCES INC
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1911336
dei Local Phone Number
LocalPhoneNumber
501-2444
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2019Q2 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2019Q3 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q2 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q3 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q1 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
2888092
CY2020Q2 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
189431
CY2020Q3 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
588235
CY2020Q3 sava Offering Costs
OfferingCosts
180000
sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
68000
CY2019Q3 sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
22500
sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
68000
CY2020Q3 sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
22500
sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
3800000
CY2019Q3 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1500000
sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
3400000
CY2020Q3 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1000000
sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
830000
CY2019Q3 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
-52000
sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
1534000
CY2020Q3 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
399000
CY2019Q1 sava Shares Issued Costs From Sale2018 Sale Of Common Stock And Warrants
SharesIssuedCostsFromSale2018SaleOfCommonStockAndWarrants
CY2019Q1 sava Stockholders Equity Issuance Of Common Stock And Warrants Net Of Issuance Costs
StockholdersEquityIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
60000
CY2020Q1 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
3613000
CY2020Q2 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
236000
CY2020Q3 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
735000
CY2020Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
86000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
453000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
465000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
777000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
558000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
878000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190664000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
196250000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
992000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24074000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
750000
CY2019Q4 us-gaap Assets
Assets
23486000
CY2020Q3 us-gaap Assets
Assets
25399000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
23349000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
25071000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19807000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17804000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23081000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2003000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
993000
CY2019Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
13000000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21841810
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25578673
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17219300
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21841810
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24729902
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24919333
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25578673
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
26000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
58000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
80000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
29000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
346000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2553000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
831000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2634000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1038000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
46000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
259000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-219000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-6000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
22000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
152000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
729000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
7000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-2000
us-gaap Interest And Other Income
InterestAndOtherIncome
268000
CY2019Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
82000
us-gaap Interest And Other Income
InterestAndOtherIncome
106000
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
7000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
268000
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0325
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
336000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
66000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
36000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
107000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
102000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
25000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20000
CY2019Q4 us-gaap Liabilities
Liabilities
1387000
CY2020Q3 us-gaap Liabilities
Liabilities
1426000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23486000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25399000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1387000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1168000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-60000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4840000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
360000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1925000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4207000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1359000
us-gaap Net Income Loss
NetIncomeLoss
-3115000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1059000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-697000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1150000
us-gaap Net Income Loss
NetIncomeLoss
-3716000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1136000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1430000
us-gaap Operating Expenses
OperatingExpenses
3383000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
779000
us-gaap Operating Expenses
OperatingExpenses
3822000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
1437000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3383000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-779000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3822000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1437000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
316000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
90000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
258000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
316000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
268000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
997000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
13000
CY2020Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
45000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
60000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19628000
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17162000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17162000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24745000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24972000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
997000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
226000
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
686000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2019Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
360000
CY2020Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
256000
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
256000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4584000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
892000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168587000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172303000
us-gaap Share Based Compensation
ShareBasedCompensation
992000
us-gaap Share Based Compensation
ShareBasedCompensation
750000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
22099000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
23973000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17823000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
22099000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24832000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24184000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23973000
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
71105
us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-family:Tahoma;font-style:italic;">&#xFEFF;</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The Company makes estimates and assumptions in preparing its </font><font style="display: inline;">condensed </font><font style="display: inline;">financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the </font><font style="display: inline;">condensed</font><font style="display: inline;"> financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&nbsp;its estimates on an ongoing basis, including those estimates related to agreements, research collaborations and investments. Actual results could differ from these estimates</font><font style="display: inline;color:#000000;"> and assumptions.</font><font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div>

Files In Submission

Name View Source Status
0001069530-20-000066-index-headers.html Edgar Link pending
0001069530-20-000066-index.html Edgar Link pending
0001069530-20-000066.txt Edgar Link pending
0001069530-20-000066-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sava-20200930.xml Edgar Link completed
sava-20200930.xsd Edgar Link pending
sava-20200930x10q.htm Edgar Link pending
sava-20200930xex31_1.htm Edgar Link pending
sava-20200930xex31_2.htm Edgar Link pending
sava-20200930xex32_1.htm Edgar Link pending
sava-20200930_cal.xml Edgar Link unprocessable
sava-20200930_def.xml Edgar Link unprocessable
sava-20200930_lab.xml Edgar Link unprocessable
sava-20200930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending